title: Recent improvements in outcome for elderly patients with de novo acute myeloblastic leukemia.
abstract: A retrospective analysis was performed on 263 consecutive patients aged over 60 with de novo acute myeloid leukemia (AML) diagnosed in a single institution between 1979 and 1998. Eighty-nine patients (33%) received only palliative treatment, while 174 patients (67%) were treated with different intensive chemotherapy regimens. The 5- and 10-year overall survival (OS) for the whole series was 7.7+/-1.2 and 4.3+/-1.6%, respectively. For patients receiving chemotherapy, OS was 10.5+/-2.5 and 7+/-2.6%, while for those patients receiving supportive treatment it was 1.1+/-1.1 and 0%, respectively (P=0.002). Within the group of patients receiving chemotherapy, the complete remission (CR) rate was 46%; treatment failure rate was 54% (36% due to treatment-related mortality and 18% due to resistant disease). Variables influencing CR rate were FAB subtype, CD7 positivity, chemotherapy regimen, creatinine level, hepatomegaly, and period of diagnosis. Median disease-free survival (DFS) duration was 8.4 months with a probability of being disease-free at 10 years of 10+/-5%. There were no significant differences in DFS according to age. According to the period of diagnosis (1979-1986 vs. 1987-1998), improvements in the CR rate (27 vs. 56%, P=0.0002), and OS (10.9 vs. 15.7 months, P=0.0007) were observed. This large single-center study of unselected de novo AML elderly patients substantiates the progressive improvement achieved in the management of elderly patients with AML, probably due to an improvement in supportive care and the administration of conventional induction chemotherapy.
authors.affiliation: Hematology Department, University Hospital La Fe, Avda. Campanar, 21, 46009, Valencia, Spain.
authors.forename: A
authors.initials: A
authors.lastname: López
authors.forename: J
authors.initials: J
authors.lastname: de la Rubia
authors.forename: G
authors.initials: G
authors.lastname: Martín
authors.forename: J
authors.initials: J
authors.lastname: Martínez
authors.forename: J
authors.initials: J
authors.lastname: Cervera
authors.forename: I
authors.initials: I
authors.lastname: Jarque
authors.forename: A
authors.initials: A
authors.lastname: Sempere
authors.forename: G
authors.initials: G
authors.lastname: Plumé
authors.forename: S
authors.initials: S
authors.lastname: Saavedra
authors.forename: A
authors.initials: A
authors.lastname: Regadera
authors.forename: G
authors.initials: G
authors.lastname: Sanz
authors.forename: F
authors.initials: F
authors.lastname: Gomis
authors.forename: M L
authors.initials: ML
authors.lastname: Pérez-Sirvent
authors.forename: L
authors.initials: L
authors.lastname: Senent
authors.forename: C
authors.initials: C
authors.lastname: Jiménez
authors.forename: M A
authors.initials: MA
authors.lastname: Sanz
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000188:drug therapy*; D015473:Leukemia, Promyelocytic, Acute / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome